Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Blasts Under 20 Percent of Peripheral Blood White Cells”

2 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 2 of 2 results

Testing effectiveness (Phase 2)Looking for participantsNCT03801434
What this trial is testing

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Who this might be right for
BCR-JAK2 Fusion Protein ExpressionBlasts 20 Percent or Less of Peripheral Blood White CellsBlasts More Than 5 Percent of Bone Marrow Nucleated Cells+9 more
William Shomali 10
Testing effectiveness (Phase 2)Study completedNCT01823198
What this trial is testing

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Erythroid LeukemiaAcute Megakaryoblastic Leukemia+12 more
M.D. Anderson Cancer Center 63